跳至主要内容
临床试验/CTRI/2019/05/019130
CTRI/2019/05/019130已完成未知

Treatment response and toxicity profile of Pemetrexed/carboplatin vs Paclitaxel/carboplatin combination chemotherapy schedule in advanced non-small cell lung cancer( adenocarcinoma) patients-A prospective observational study.

Government medical college hospital Trivandrum0 个研究点目标入组 151 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
151

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Histologically confirmed cases of non small cell lung cancer â??adenocarcinoma
  • 2.Stage 3B and Stage 4.
  • 3.EGFR nonmutated or not done.
  • 4.Eastern cooperative oncology group (ECOG) performance status of 1 or 2.
  • 5.Previously untreated cases.
  • 6.Normal bone marrow function(Hb >10, TC >4000, PLC >1Lakh)
  • 7.Normal renal function (serum creatinine < 1.6)
  • 8.Normal liver function.

排除标准

  • 1.Patients not willing to give a written consent.
  • 2.History of previous malignancies treated or untreated.
  • 3.Clinically significant cardiovascular disease, haemorrhagic diasthesis ,peripheral neuropathy ,coagulopathy.
  • 4.EGFR mutated.

研究者

发起方
Government medical college hospital Trivandrum

相似试验